Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
Regensburger M, Ip CW, Kohl Z, Schrader C, Urban PP, Kassubek J, Jost WH (2023)
Publication Type: Journal article, Review article
Publication year: 2023
Journal
DOI: 10.1007/s00702-023-02623-8
Abstract
Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are major strategies to reduce levodopa degradation and thus to increase and prolong its effect in striatal dopaminergic neurotransmission in Parkinson’s disease patients. While selegiline/rasagiline and tolcapone/entacapone have been available on the market for more than one decade, safinamide and opicapone have been approved in 2015 and 2016, respectively. Meanwhile, comprehensive data from several post-authorization studies have described the use and specific characteristics of the individual substances in clinical practice under real-life conditions. Here, we summarize current knowledge on both medication classes, with a focus on the added clinical value in Parkinson’s disease. Furthermore, we outline practical considerations in the treatment of motor fluctuations and provide an outlook on ongoing studies with MAO-B and COMT inhibitors.
Authors with CRIS profile
Additional Organisation(s)
Involved external institutions
Universitätsklinikum Würzburg
Germany (DE)
Universität Regensburg
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Asklepios Kliniken
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Parkinson-Klinik Ortenau
Germany (DE)
Germany (DE)
Universität Regensburg
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Asklepios Kliniken
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Parkinson-Klinik Ortenau
Germany (DE)
How to cite
APA:
Regensburger, M., Ip, C.W., Kohl, Z., Schrader, C., Urban, P.P., Kassubek, J., & Jost, W.H. (2023). Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations. Journal of Neural Transmission. https://doi.org/10.1007/s00702-023-02623-8
MLA:
Regensburger, Martin, et al. "Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations." Journal of Neural Transmission (2023).
BibTeX: Download